USANA Health Sciences Reports First Quarter 2024 Results

SALT LAKE CITY--()--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 30, 2024.

Key Financial & Operating Results

  • First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency.
  • First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023.
  • Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00.

Q1 2024 Financial Performance

Consolidated Results

Net Sales

$228 million

  • -8% vs. Q1 2023

 

 

  • -5% constant currency vs. Q1 2023

 

 

  • +3% sequentially

 

 

  • +2% constant currency sequentially

 

 

  • -$7 million YOY FX impact, or -3%

Diluted EPS

$0.86

  • -9% vs. Q1 2023

 

 

  • -1% sequentially

Active Customers

494,000

  • +1% vs. Q1 2023

 

 

  • +2% sequentially

“Our top line results during the first quarter were driven by a successful sales incentive in mainland China, which helped counter the seasonal slowdown that we experience during the Lunar New Year holiday,” said Jim Brown, President and Chief Executive Officer. “This sales incentive helped us generate 15% year-over-year active customer growth in our largest market, as well as year-over-year and sequential quarter sales growth. Notwithstanding our solid performance in China, our first quarter results in other key markets did not meet internal expectations and we are actively working to accelerate our business in these markets during 2024.

“During the first quarter we focused on actively engaging with our Associate leaders across the world through several live annual kickoff events, meetings, and trainings. Moreover, early in the second quarter, we hosted both our China National Sales Meeting in Xiamen, China and our Asia Pacific Convention in Kuala Lampur, Malaysia. Attendance at both events was robust and our executive team and Associate leaders came away from both events with increased excitement and motivation to grow their businesses during 2024. We will host additional Associate events throughout the year; all intended to drive further engagement with and productivity from our Associate leaders.

“We also completed our first full quarter of operations in India and we remain excited and optimistic about this important market. We continue to work closely with our local leadership team to expand and build our presence throughout the country. Although we expect its contribution to be small in this first year, we have high expectations for steady and long-term growth in India.”

Q1 2024 Regional Results:

Asia Pacific Region

Net Sales

$185 million

  • -7% vs. Q1 2023

 

 

  • -3% constant currency vs. Q1 2023

 

 

  • +5% sequentially

 

 

  • 81% of consolidated net sales

Active Customers

395,000

  • +2% vs. Q1 2023

 

 

  • +3% sequentially

Asia Pacific Sub-Regions

Greater China

Net Sales

$128 million

  • +3% vs. Q1 2023

 

 

  • +7% constant currency vs. Q1 2023

 

 

  • +10% sequentially

Active Customers

274,000

  • +13% vs. Q1 2023

 

 

  • +7% sequentially

North Asia

Net Sales

$21 million

  • -28% vs. Q1 2023

 

 

  • -24% constant currency vs. Q1 2023

 

 

  • -3% sequentially

Active Customers

45,000

  • -17% vs. Q1 2023

 

 

  • -6% sequentially

Southeast Asia Pacific

Net Sales

$36 million

  • -22% vs. Q1 2023

 

 

  • -19% constant currency vs. Q1 2023

 

 

  • -8% sequentially

Active Customers

76,000

  • -16% vs. Q1 2023

 

 

  • -5% sequentially

Americas and Europe Region

Net Sales

$43 million

  • -12% vs. Q1 2023

 

 

  • -14% constant currency vs. Q1 2023

 

 

  • -3% sequentially

 

 

  • 19% of consolidated net sales

Active Customers

99,000

  • -6% vs. Q1 2023

 

 

  • -1% sequentially

Balance Sheet and Share Repurchase Activity

The Company generated $18 million in operating cash flow during first quarter and ended the quarter with $328 million in cash and cash equivalents while remaining essentially debt-free. The Company repurchased 194,000 shares for a total of $9 million during the quarter. As of March 30, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

Fiscal Year 2024 Outlook

The Company is reiterating its net sales and earnings per share outlook for fiscal year 2024, as follows:

Fiscal Year 2024 Outlook

 

Range

Consolidated Net Sales

$850 - $920 million

Diluted EPS

$2.40 - $3.00

“Strength in our mainland China operations carried our first quarter results,” said Doug Hekking, Chief Financial Officer. “This performance helped offset softness in many other markets where we continue to face a challenging operating environment highlighted by ongoing inflationary pressures.”

Mr. Hekking continued, “We remain committed to engaging with Associate leaders throughout each of our markets and plan to offer additional market-specific incentives throughout the year to improve sales and customer activity levels.”

Management Commentary Document and Conference Call

For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, May 1, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Non-GAAP Financial Measures

The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 

 

 

 

Quarter Ended

 

 

March 30,
2024

 

April 1,
2023

 

Net sales

$

227,800

 

 

$

248,360

 

 

Cost of sales

 

43,069

 

 

 

48,519

 

 

Gross profit

 

184,731

 

 

 

199,841

 

 

Operating expenses:

 

 

 

 

Associate incentives

 

95,758

 

 

 

106,070

 

 

Selling, general and administrative

 

64,300

 

 

 

66,926

 

 

Total operating expenses

 

160,058

 

 

 

172,996

 

 

Earnings from operations

 

24,673

 

 

 

26,845

 

 

Other income (expense):

 

 

 

 

Interest income

 

2,676

 

 

 

1,775

 

 

Interest expense

 

(52

)

 

 

(31

)

 

Other, net

 

(186

)

 

 

(88

)

 

Other income (expense), net

 

2,438

 

 

 

1,656

 

 

Earnings before income taxes

 

27,111

 

 

 

28,501

 

 

Income taxes

 

10,574

 

 

 

10,118

 

 

Net earnings

$

16,537

 

 

$

18,383

 

 

 

 

 

 

 

Earnings per common share

 

 

 

 

Basic

$

0.86

 

 

$

0.95

 

 

Diluted

$

0.86

 

 

$

0.95

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

Basic

 

19,174

 

 

 

19,283

 

 

Diluted

 

19,302

 

 

 

19,328

 

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

 

 

As of
March 30,
2024

 

As of
December 30,
2023

ASSETS

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

328,336

 

$

330,420

Inventories

 

60,870

 

 

61,454

Prepaid expenses and other current assets

 

31,864

 

 

25,872

Total current assets

 

421,070

 

 

417,746

Property and equipment, net

 

98,186

 

 

99,814

Goodwill

 

16,902

 

 

17,102

Intangible assets, net

 

29,105

 

 

29,919

Deferred tax assets

 

11,347

 

 

13,284

Other assets*

 

52,665

 

 

54,892

Total assets

$

629,275

 

$

632,757

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

Current liabilities

 

 

 

Accounts payable

$

8,266

 

$

10,070

Line of credit - short term

 

1,320

 

 

786

Other current liabilities

 

103,045

 

 

107,989

Total current liabilities

 

112,631

 

 

118,845

Deferred tax liabilities

 

5,113

 

 

4,552

Other long-term liabilities

 

11,543

 

 

12,158

 

 

 

 

Stockholders' equity

 

499,988

 

 

497,202

Total liabilities and stockholders' equity

$

629,275

 

$

632,757

*Other assets include noncurrent inventories of $2,893 and $3,128 as of 30-Mar-24 and 30-Dec-23, respectively. Total inventories were $63,763 and $64,582 as of 30-Mar-24 and 30-Dec-23, respectively.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

SALES BY REGION

(in thousands)

(unaudited)

 

 

Quarter Ended

 

Change from prior

year

 

Percent change

 

Currency impact on

sales

 

% change

excluding currency

impact

 

March 30, 2024

 

April 1, 2023

 

 

 

 

Asia Pacific

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Greater China

$

127,615

 

56.0

%

 

$

123,820

 

49.9

%

 

$

3,795

 

 

3.1

%

 

$

(5,396

)

 

7.4

%

Southeast Asia Pacific

 

36,065

 

15.9

%

 

$

46,286

 

18.6

%

 

 

(10,221

)

 

(22.1

%)

 

 

(1,495

)

 

(18.9

%)

North Asia

 

21,421

 

9.4

%

 

$

29,608

 

11.9

%

 

 

(8,187

)

 

(27.7

%)

 

 

(987

)

 

(24.3

%)

Asia Pacific Total

 

185,101

 

81.3

%

 

 

199,714

 

80.4

%

 

 

(14,613

)

 

(7.3

%)

 

 

(7,878

)

 

(3.4

%)

Americas and Europe

 

42,699

 

18.7

%

 

 

48,646

 

19.6

%

 

 

(5,947

)

 

(12.2

%)

 

 

635

 

 

(13.5

%)

 

$

227,800

 

100.0

%

 

$

248,360

 

100.0

%

 

$

(20,560

)

 

(8.3

%)

 

$

(7,243

)

 

(5.4

%)

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION

(unaudited)

 

Active Associates by Region(1)

(unaudited)

 

As of
March 30, 2024

 

As of
April 1, 2023

Asia Pacific:

 

 

 

 

 

 

 

Greater China

71,000

 

36.1

%

 

74,000

 

34.1

%

Southeast Asia Pacific

51,000

 

25.9

%

 

61,000

 

28.1

%

North Asia

30,000

 

15.2

%

 

35,000

 

16.1

%

Asia Pacific Total

152,000

 

77.2

%

 

170,000

 

78.3

%

 

 

 

 

 

 

 

 

Americas and Europe

45,000

 

22.8

%

 

47,000

 

21.7

%

 

197,000

 

100.0

%

 

217,000

 

100.0

%

Active Preferred Customers by Region(2)

(unaudited)

 

As of
March 30, 2024

 

As of
April 1, 2023

Asia Pacific:

 

 

 

 

 

 

 

Greater China

203,000

 

68.3

%

 

168,000

 

61.3

%

Southeast Asia Pacific

25,000

 

8.4

%

 

29,000

 

10.6

%

North Asia

15,000

 

5.1

%

 

19,000

 

6.9

%

Asia Pacific Total

243,000

 

81.8

%

 

216,000

 

78.8

%

 

 

 

 

 

 

 

 

Americas and Europe

54,000

 

18.2

%

 

58,000

 

21.2

%

 

297,000

 

100.0

%

 

274,000

 

100.0

%

(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

Contacts

Investor contact:

Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com

Media contact:

Amy Haran
Public Relations
(801) 954-7280

Contacts

Investor contact:

Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com

Media contact:

Amy Haran
Public Relations
(801) 954-7280